Literature DB >> 26099573

Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.

Yinghui Wei1,2, Patrick Royston1, Jayne F Tierney1, Mahesh K B Parmar1.   

Abstract

Meta-analysis of time-to-event outcomes using the hazard ratio as a treatment effect measure has an underlying assumption that hazards are proportional. The between-arm difference in the restricted mean survival time is a measure that avoids this assumption and allows the treatment effect to vary with time. We describe and evaluate meta-analysis based on the restricted mean survival time for dealing with non-proportional hazards and present a diagnostic method for the overall proportional hazards assumption. The methods are illustrated with the application to two individual participant meta-analyses in cancer. The examples were chosen because they differ in disease severity and the patterns of follow-up, in order to understand the potential impacts on the hazards and the overall effect estimates. We further investigate the estimation methods for restricted mean survival time by a simulation study.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  meta-analysis; non-proportional hazards; restricted mean survival time; time-to-event outcomes

Mesh:

Year:  2015        PMID: 26099573      PMCID: PMC5695659          DOI: 10.1002/sim.6556

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  44 in total

1.  Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

Review 2.  Pseudo-observations in survival analysis.

Authors:  Per Kragh Andersen; Maja Pohar Perme
Journal:  Stat Methods Med Res       Date:  2009-08-04       Impact factor: 3.021

3.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

4.  Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2.

Authors:  Amir Sherif; Erkki Rintala; Oddvar Mestad; Jonas Nilsson; Lars Holmberg; Sten Nilsson; Per-Uno Malmström
Journal:  Scand J Urol Nephrol       Date:  2002

5.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

6.  A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304).

Authors:  Hirohito Tada; Ryosuke Tsuchiya; Yukito Ichinose; Teruaki Koike; Nobuhiro Nishizawa; Kanji Nagai; Harubumi Kato
Journal:  Lung Cancer       Date:  2004-02       Impact factor: 5.705

7.  Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

Authors:  D Waller; M D Peake; R J Stephens; N H Gower; R Milroy; M K B Parmar; R M Rudd; S G Spiro
Journal:  Eur J Cardiothorac Surg       Date:  2004-07       Impact factor: 4.191

8.  Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.

Authors:  R Feld; L Rubinstein; P A Thomas
Journal:  J Natl Cancer Inst       Date:  1993-02-17       Impact factor: 13.506

9.  A phase 3 randomized trial of immediate combination chemotherapy vs delayed combination chemotherapy in patients with completely resected stage II and III non-small cell carcinoma of the lung.

Authors:  R A Figlin; S Piantodosi
Journal:  Chest       Date:  1994-12       Impact factor: 9.410

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  13 in total

Review 1.  Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

Authors:  D De Ruysscher; B Lueza; C Le Péchoux; D H Johnson; M O'Brien; N Murray; S Spiro; X Wang; M Takada; B Lebeau; W Blackstock; D Skarlos; P Baas; H Choy; A Price; L Seymour; R Arriagada; J-P Pignon
Journal:  Ann Oncol       Date:  2016-07-19       Impact factor: 32.976

2.  What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.

Authors:  Laureen Ribassin-Majed; Sophie Marguet; Anne W M Lee; Wai Tong Ng; Jun Ma; Anthony T C Chan; Pei-Yu Huang; Guopei Zhu; Daniel T T Chua; Yong Chen; Hai-Qiang Mai; Dora L W Kwong; Shie-Lee Cheah; James Moon; Yuk Tung; Kwan-Hwa Chi; George Fountzilas; Jean Bourhis; Jean Pierre Pignon; Pierre Blanchard
Journal:  J Clin Oncol       Date:  2016-12-05       Impact factor: 44.544

3.  Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study.

Authors:  Béranger Lueza; Audrey Mauguen; Jean-Pierre Pignon; Oliver Rivero-Arias; Julia Bonastre
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

4.  Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models.

Authors:  Suzanne C Freeman; James R Carpenter
Journal:  Res Synth Methods       Date:  2017-07-25       Impact factor: 5.273

5.  Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas.

Authors:  C Petit; P Blanchard; J P Pignon; B Lueza
Journal:  Syst Rev       Date:  2019-04-15

6.  Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies.

Authors:  Mohammed Dagher; Meritxell Sabidó; York Zöllner
Journal:  J Cancer Res Clin Oncol       Date:  2019-06-14       Impact factor: 4.553

7.  Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds.

Authors:  Denis L Jardim; Débora De Melo Gagliato; Mina Nikanjam; Donald A Barkauskas; Razelle Kurzrock
Journal:  Oncoimmunology       Date:  2020-01-13       Impact factor: 8.110

8.  Reconstructing time-to-event data from published Kaplan-Meier curves.

Authors:  Yinghui Wei; Patrick Royston
Journal:  Stata J       Date:  2017-10       Impact factor: 2.637

9.  Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.

Authors:  Béranger Lueza; Federico Rotolo; Julia Bonastre; Jean-Pierre Pignon; Stefan Michiels
Journal:  BMC Med Res Methodol       Date:  2016-03-29       Impact factor: 4.615

Review 10.  Individual participant data meta-analysis of intervention studies with time-to-event outcomes: A review of the methodology and an applied example.

Authors:  Valentijn M T de Jong; Karel G M Moons; Richard D Riley; Catrin Tudur Smith; Anthony G Marson; Marinus J C Eijkemans; Thomas P A Debray
Journal:  Res Synth Methods       Date:  2020-02-06       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.